Pricing Log in Create free account
Friday 6 November 2026 Export KYMR’s income statement to Excel — free account

Kymera Therapeutics, Inc.

KYMR Healthcare Biotechnology

Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024.

Revenue
+466.4%
EPS
−40.3%
Free cash flow
−186.6%
Total debt
−66.6%

Quarter to September 2026, against a year earlier

132.05 3.93 +3.07%
Market cap
$10.9B
P/E
0.0×
Fwd P/E
−31.6×
Dividend yield
—
F-score
4/9
Altman Z
23.22
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Kymera Therapeutics, Inc. 10-Q filed Oct 31, 2024

Fiscal Q3 2024 · Period ended Sep 30, 2024 · Filed · accepted 7:45 AM ET · Document on sec.gov · Filing index

Nothing in this filing raised a red flag. The document itself is on sec.gov.

Read the filing on sec.gov